Logo image of CGEN

COMPUGEN LTD (CGEN) Stock Fundamental Analysis

NASDAQ:CGEN - Nasdaq - IL0010852080 - Common Stock - Currency: USD

1.4  -0.01 (-0.71%)

Fundamental Rating

4

Taking everything into account, CGEN scores 4 out of 10 in our fundamental rating. CGEN was compared to 561 industry peers in the Biotechnology industry. While CGEN seems to be doing ok healthwise, there are quite some concerns on its profitability. CGEN does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

CGEN had negative earnings in the past year.
In the past year CGEN had a positive cash flow from operations.
CGEN had negative earnings in each of the past 5 years.
In the past 5 years CGEN reported 4 times negative operating cash flow.
CGEN Yearly Net Income VS EBIT VS OCF VS FCFCGEN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

1.2 Ratios

CGEN has a better Return On Assets (-12.38%) than 83.60% of its industry peers.
With an excellent Return On Equity value of -25.92%, CGEN belongs to the best of the industry, outperforming 81.28% of the companies in the same industry.
Industry RankSector Rank
ROA -12.38%
ROE -25.92%
ROIC N/A
ROA(3y)-21.2%
ROA(5y)-22.19%
ROE(3y)-32.63%
ROE(5y)-30.94%
ROIC(3y)N/A
ROIC(5y)N/A
CGEN Yearly ROA, ROE, ROICCGEN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

CGEN has a Gross Margin of 71.54%. This is amongst the best in the industry. CGEN outperforms 82.00% of its industry peers.
CGEN's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for CGEN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 71.54%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-6.9%
GM growth 5YN/A
CGEN Yearly Profit, Operating, Gross MarginsCGEN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K

More info and screens

6

2. Health

2.1 Basic Checks

CGEN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CGEN has been increased compared to 1 year ago.
Compared to 5 years ago, CGEN has more shares outstanding
There is no outstanding debt for CGEN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CGEN Yearly Shares OutstandingCGEN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
CGEN Yearly Total Debt VS Total AssetsCGEN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

CGEN has an Altman-Z score of -3.98. This is a bad value and indicates that CGEN is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -3.98, CGEN is in line with its industry, outperforming 44.56% of the companies in the same industry.
There is no outstanding debt for CGEN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z -3.98
ROIC/WACCN/A
WACC9.02%
CGEN Yearly LT Debt VS Equity VS FCFCGEN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

CGEN has a Current Ratio of 5.26. This indicates that CGEN is financially healthy and has no problem in meeting its short term obligations.
CGEN's Current ratio of 5.26 is in line compared to the rest of the industry. CGEN outperforms 57.22% of its industry peers.
A Quick Ratio of 5.26 indicates that CGEN has no problem at all paying its short term obligations.
CGEN's Quick ratio of 5.26 is in line compared to the rest of the industry. CGEN outperforms 58.11% of its industry peers.
Industry RankSector Rank
Current Ratio 5.26
Quick Ratio 5.26
CGEN Yearly Current Assets VS Current LiabilitesCGEN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 15.79% over the past year.
CGEN shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -16.72%.
Measured over the past years, CGEN shows a very strong growth in Revenue. The Revenue has been growing by 66.84% on average per year.
EPS 1Y (TTM)15.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)-16.72%
Revenue growth 3Y66.84%
Revenue growth 5YN/A
Sales Q2Q%-10.9%

3.2 Future

The Earnings Per Share is expected to decrease by -19.98% on average over the next years. This is quite bad
CGEN is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 2.30% yearly.
EPS Next Y25.62%
EPS Next 2Y13.96%
EPS Next 3Y15.29%
EPS Next 5Y-19.98%
Revenue Next Year-30.62%
Revenue Next 2Y-5.63%
Revenue Next 3Y2.48%
Revenue Next 5Y2.3%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
CGEN Yearly Revenue VS EstimatesCGEN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 20M 40M 60M 80M 100M
CGEN Yearly EPS VS EstimatesCGEN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 -0.2 -0.4 -0.6

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CGEN. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CGEN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CGEN Price Earnings VS Forward Price EarningsCGEN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Based on the Price/Free Cash Flow ratio, CGEN is valued cheaper than 99.82% of the companies in the same industry.
Industry RankSector Rank
P/FCF 2.53
EV/EBITDA N/A
CGEN Per share dataCGEN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 0.4 0.6

4.3 Compensation for Growth

CGEN's earnings are expected to grow with 15.29% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y13.96%
EPS Next 3Y15.29%

More info and screens

0

5. Dividend

5.1 Amount

CGEN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

COMPUGEN LTD

NASDAQ:CGEN (5/21/2025, 10:12:45 AM)

1.4

-0.01 (-0.71%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-19 2025-05-19/bmo
Earnings (Next)08-04 2025-08-04
Inst Owners14.98%
Inst Owner Change23.68%
Ins Owners0.06%
Ins Owner ChangeN/A
Market Cap125.36M
Analysts88
Price Target4.85 (246.43%)
Short Float %1.96%
Short Ratio6.56
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-142.14%
Min EPS beat(2)-193.59%
Max EPS beat(2)-90.69%
EPS beat(4)1
Avg EPS beat(4)-117.3%
Min EPS beat(4)-256.51%
Max EPS beat(4)71.58%
EPS beat(8)3
Avg EPS beat(8)-64.31%
EPS beat(12)6
Avg EPS beat(12)-35.62%
EPS beat(16)10
Avg EPS beat(16)-21.03%
Revenue beat(2)0
Avg Revenue beat(2)-48.85%
Min Revenue beat(2)-91.73%
Max Revenue beat(2)-5.97%
Revenue beat(4)1
Avg Revenue beat(4)1.59%
Min Revenue beat(4)-91.73%
Max Revenue beat(4)163.65%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-5%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-10%
EPS NY rev (1m)0%
EPS NY rev (3m)2.78%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-25.92%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-9.05%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.5
P/FCF 2.53
P/OCF 2.53
P/B 2.28
P/tB 2.28
EV/EBITDA N/A
EPS(TTM)-0.16
EYN/A
EPS(NY)-0.11
Fwd EYN/A
FCF(TTM)0.55
FCFY39.48%
OCF(TTM)0.55
OCFY39.57%
SpS0.31
BVpS0.61
TBVpS0.61
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -12.38%
ROE -25.92%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 71.54%
FCFM 177.6%
ROA(3y)-21.2%
ROA(5y)-22.19%
ROE(3y)-32.63%
ROE(5y)-30.94%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-6.9%
GM growth 5YN/A
F-Score5
Asset Turnover0.24
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA N/A
Cap/Depr 24.28%
Cap/Sales 0.42%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.26
Quick Ratio 5.26
Altman-Z -3.98
F-Score5
WACC9.02%
ROIC/WACCN/A
Cap/Depr(3y)54.17%
Cap/Depr(5y)49.83%
Cap/Sales(3y)2.49%
Cap/Sales(5y)4.16%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)15.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y25.62%
EPS Next 2Y13.96%
EPS Next 3Y15.29%
EPS Next 5Y-19.98%
Revenue 1Y (TTM)-16.72%
Revenue growth 3Y66.84%
Revenue growth 5YN/A
Sales Q2Q%-10.9%
Revenue Next Year-30.62%
Revenue Next 2Y-5.63%
Revenue Next 3Y2.48%
Revenue Next 5Y2.3%
EBIT growth 1Y-14.69%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y237.24%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y238.23%
OCF growth 3YN/A
OCF growth 5YN/A